Life history of retrocopies [incl. ~5k #pseudogenes]
illuminates…evolution
http://genome.cshlp.org/content/early/2016/01/04/gr.198473.115 Suggests modes of promotor acquisition
[tag
from,fn,from_fn,jclub,pseudogenes,u41pg,evolution,gencode,cmppgene]
longest episode !
https://en.wikipedia.org/wiki/A_Little_Kiss
New grant format w/ prelim. results under significance v. approach as nowhttp://grants.nih.gov/grants/guide/notice-files/NOT-OD-16-011.html @NIH notice is cryptic. People’s thoughts?
+
need to use strength & weakness for each citation.
see also:
http://www.grantcentral.com/wp-content/uploads/2015/12/Supplement-Changes-in-Approach-Subsection.pdf http://grants.nih.gov/grants/forms_updates_faq.htm#2426
http://grants.nih.gov/grants/funding/424/index.htm
QT:{{”
One of the changes to this Chapter pertains to the format for the Approach subsection, which is reproduced, above. “Justification and Feasibility” and its two subdivisions have been lined out because, with the new approach that we recommend, they are no longer part of the Approach subsection. (We have moved them to the Significance subsection, Chapter 9). Without those components, the formatting for each aim “collapses” to include the Introductory Paragraph, Research Design, Expected Outcomes and Potential Problems & Alternative Strategies.
“}}
&
QT:{{”
Updates to Research Strategy Guidance
By November 25, 2015 application guide instructions will be updated to include the following additional guidance for the Significance and Approach sections of the Research Strategy, in addition to the existing instructions.
Significance
Describe the scientific premise for the proposed project, including consideration of the strengths and weaknesses of published research or preliminary data crucial to the support of your application. Approach
Describe the experimental design and methods proposed and how they will achieve robust and unbiased results.
“}}
http://www.medicarearticles.com/do-you-know-what-the-10-most-expensive-medicare-part-b-drugs-are
QT:{{”
5. Erbitux
Treats: cancer
Cost: $25,898
4. Primacor, Primacor in Dextrose
Treats: acute decompensated heart failure
Cost: $62,790
3. Ventavis
Treats: pulmonary arterial hypertension
Cost: $84,205
2. Remodulin
Treats: pulmonary arterial hypertension
Cost: $130,772
1. Factor viii Recombinant (various)
Treats: hemophilia A
Cost: $216,833
“}}
contains broken link to GAO report –
http://www.medicarenewsgroup.com/news/medicare-faqs/individual-faq?faqId=48ec6c39-e49a-4bb9-a892-19a6abac8237
Reprogramming…#epigenome & transcriptome in…muscle after training http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4622000/ Delta(Me) from #exercise in 1 leg v. other
QT:{{”
Exercise has long been known to have an effect on health, lowering the incidence of cardiovascular disease, obesity, and type 2 diabetes. Recently, it has been found that exercise can have a direct effect on DNA methylation and gene expression. A group of 23 subjects exercised one leg but not the other for 45 minutes four times a week for three months. At the end of this period, the methylation and gene expression patterns were different in the exercised leg relative to the one that did not exercise, indicating a direct effect of exercise on
epigenetics.
“}}
Quote from:
QT:{{”
There is a lot of overlap between the terms “precision medicine” and “personalized medicine.” According to the National Research Council, “personalized medicine” is an older term with a meaning similar to “precision medicine.” However, there was concern that the word “personalized” could be misinterpreted to imply that treatments and preventions are being developed uniquely for each individual; in precision medicine, the focus is on identifying which approaches will be effective for which patients based on genetic, environmental, and lifestyle factors. The Council therefore preferred the term “precision medicine” to “personalized medicine.”
“}}
http://ghr.nlm.nih.gov/handbook/precisionmedicine/precisionvspersonalized